Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;20(6):957-964.
doi: 10.1016/j.jcf.2021.04.006. Epub 2021 Jun 1.

Respiratory symptoms do not reflect functional impairment in early CF lung disease

Affiliations
Free article

Respiratory symptoms do not reflect functional impairment in early CF lung disease

Insa Korten et al. J Cyst Fibros. 2021 Nov.
Free article

Abstract

Background: Lung disease can develop within the first year of life in infants with cystic fibrosis (CF). However, the frequency and severity of respiratory symptoms in infancy are not known.

Methods: We assessed respiratory symptoms in 50 infants with CF and 50 healthy matched controls from two prospective birth cohort studies. Respiratory symptoms and respiratory rate were documented by standardized weekly interviews throughout the first year. Infants performed multiple breath washout in the first weeks of life.

Results: We analyzed 4552 data points (2217 in CF). Respiratory symptoms (either mild or severe) were not more frequent in infants with CF (OR:1.1;95% CI:[0.76, 1.59]; p=0.6). Higher lung clearance index and higher respiratory rate in infants with CF were not associated with respiratory symptoms.

Conclusions: We found no difference in respiratory symptoms between healthy and CF infants. These data indicate that early CF lung disease may not be captured by clinical presentation alone.

Keywords: Cohort study; Cystic fibrosis; Healthy controls; Infancy; Respiratory symptoms.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr. Latzin reports personal fees from Gilead, personal fees from Novartis, OM Pharma, Polyphor, Roche, Santhera, Schwabe, Vertex, Vifor, Zambon and grants from Vertex, outside the submitted work.

Comment in

Publication types